Drug Information

Drug General Information
Drug ID
D05HWN
Former ID
DIB016890
Drug Name
BIIB-021
Synonyms
CNF-2024; CNF-3647; EC-129; EC-137; EC-138; EC-141; EC-144; EC-146; EC-147; EC-151; EC-78; EC-89; EC-145, Conforma; EC-82, Conforma; Hsp90 inhibitor (cancer), Biogen Idec; Synthetic Hsp90 inhibitors (cancer), Conforma; Hsp90 inhibitors (synthetic, cancer), Conforma
Drug Type
Small molecular drug
Indication Breast cancer [ICD9: 174, 175; ICD10:C50] Phase 2 [522229]
Company
Conforma Therapeutics Corp
Formula
C14H15ClN6O
Canonical SMILES
c12c(ncn1Cc1c(c(c(cn1)C)OC)C)c(nc(n2)N)Cl
PubChem Compound ID
16736529
Target and Pathway
Target(s) Heat shock protein HSP90 Target Info Inhibitor [530083]
References
Ref 522229ClinicalTrials.gov (NCT00618319) An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST). U.S. National Institutes of Health.
Ref 530083BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.